SG11201809674QA - Adenine derivatives as protein kinase inhibitors - Google Patents
Adenine derivatives as protein kinase inhibitorsInfo
- Publication number
- SG11201809674QA SG11201809674QA SG11201809674QA SG11201809674QA SG11201809674QA SG 11201809674Q A SG11201809674Q A SG 11201809674QA SG 11201809674Q A SG11201809674Q A SG 11201809674QA SG 11201809674Q A SG11201809674Q A SG 11201809674QA SG 11201809674Q A SG11201809674Q A SG 11201809674QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- protein kinase
- pharmaceutically acceptable
- formula
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305530 | 2016-05-04 | ||
| PCT/EP2017/060730 WO2017191297A1 (en) | 2016-05-04 | 2017-05-04 | Adenine derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809674QA true SG11201809674QA (en) | 2018-11-29 |
Family
ID=55953089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809674QA SG11201809674QA (en) | 2016-05-04 | 2017-05-04 | Adenine derivatives as protein kinase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11236093B2 (ja) |
| EP (1) | EP3452477B1 (ja) |
| KR (1) | KR102479746B1 (ja) |
| CN (1) | CN109311882B (ja) |
| AU (1) | AU2017260298B9 (ja) |
| BR (1) | BR112018072468A2 (ja) |
| CA (1) | CA3022896A1 (ja) |
| EA (1) | EA201892460A1 (ja) |
| IL (1) | IL262700B (ja) |
| MX (1) | MX2018013325A (ja) |
| SG (1) | SG11201809674QA (ja) |
| WO (1) | WO2017191297A1 (ja) |
| ZA (1) | ZA201808014B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018019681A1 (en) * | 2016-07-25 | 2018-02-01 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| US20210147405A1 (en) * | 2017-06-14 | 2021-05-20 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
| WO2020221334A1 (en) * | 2019-04-30 | 2020-11-05 | City University Of Hong Kong | Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
| EP4006028A4 (en) | 2019-07-26 | 2022-09-14 | Zhuhai Yufan Biotechnologies Co., Ltd | IRAK4 KINASE INHIBITOR AND METHOD FOR PREPARING IT |
| CN111560389B (zh) * | 2020-06-11 | 2022-07-01 | 云南中烟工业有限责任公司 | 烟草丝裂原活化蛋白激酶基因NtMAPK8及其应用 |
| AU2022292554A1 (en) | 2021-06-14 | 2024-01-04 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010404D0 (en) | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2005009348A2 (en) | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2014077784A1 (en) | 2012-11-19 | 2014-05-22 | Agency For Science, Technology And Research | Method of treating cancer |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
-
2017
- 2017-05-04 BR BR112018072468-8A patent/BR112018072468A2/pt active Search and Examination
- 2017-05-04 CA CA3022896A patent/CA3022896A1/en active Pending
- 2017-05-04 MX MX2018013325A patent/MX2018013325A/es unknown
- 2017-05-04 SG SG11201809674QA patent/SG11201809674QA/en unknown
- 2017-05-04 CN CN201780033173.5A patent/CN109311882B/zh active Active
- 2017-05-04 US US16/097,805 patent/US11236093B2/en active Active
- 2017-05-04 WO PCT/EP2017/060730 patent/WO2017191297A1/en active Search and Examination
- 2017-05-04 EA EA201892460A patent/EA201892460A1/ru unknown
- 2017-05-04 AU AU2017260298A patent/AU2017260298B9/en active Active
- 2017-05-04 KR KR1020187034306A patent/KR102479746B1/ko active IP Right Grant
- 2017-05-04 EP EP17722013.4A patent/EP3452477B1/en active Active
-
2018
- 2018-10-31 IL IL262700A patent/IL262700B/en unknown
- 2018-11-27 ZA ZA2018/08014A patent/ZA201808014B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109311882A (zh) | 2019-02-05 |
| MX2018013325A (es) | 2019-08-16 |
| IL262700A (en) | 2018-12-31 |
| KR102479746B1 (ko) | 2022-12-21 |
| EA201892460A1 (ru) | 2019-09-30 |
| CA3022896A1 (en) | 2017-11-09 |
| ZA201808014B (en) | 2020-02-26 |
| US11236093B2 (en) | 2022-02-01 |
| KR20190003968A (ko) | 2019-01-10 |
| JP2019516688A (ja) | 2019-06-20 |
| AU2017260298B9 (en) | 2021-09-30 |
| EP3452477B1 (en) | 2023-09-13 |
| IL262700B (en) | 2022-02-01 |
| AU2017260298B2 (en) | 2021-09-02 |
| US20190127379A1 (en) | 2019-05-02 |
| EP3452477C0 (en) | 2023-09-13 |
| AU2017260298A1 (en) | 2018-12-13 |
| WO2017191297A1 (en) | 2017-11-09 |
| BR112018072468A2 (pt) | 2019-02-19 |
| CN109311882B (zh) | 2022-02-11 |
| EP3452477A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809674QA (en) | Adenine derivatives as protein kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof |